Angiogenic role of miR-20a in breast cancer by Gines Luengo-Gil (5059052)

“…</p><p>Results</p><p><i>In vitro</i> angiogenesis assays with endothelial cells and conditioned media from breast cancer cell lines showed that transfection with anti-miR20a in MDA-MB-231 significantly decreased mean mesh size and total mesh area, while transfection with miR-20a in MCF7 cells increased mean mesh size. …”

Estimated mean values for light interception. by Torsten Schober (20485754)

Intrathecal delivery of IL-6 increases cAMP and AC levels and decreases PDE level in the sensorimotor cortex. by Ping Yang (56755)

“…<p>Seven days after intrathecal delivery of IL-6, IL-6 and AG-490, or saline, cAMP, AC and PDE levels in the sensorimotor cortex were determined by ELISA. cAMP (A) and AC (C) levels increased while PDE (B) level decreased in IL-6 delivery group compared with that of saline group. …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

RNA Interference in <em>Schistosoma mansoni</em> Schistosomula: Selectivity, Sensitivity and Operation for Larger-Scale Screening by Saša Štefanić (239531)

“…Transient RNAi has emerged as a straightforward and important technique to interrogate that information through decreased or loss of gene function and identify potential drug targets. …”